A study of older adults found that cognitive decline, particularly in processing speed, can appear three to eight years before cardiovascular disease (CVD) events. Published in JAMA Network Open, the ...

Older adults who experienced cardiovascular disease (CVD) events experienced lower cognitive function between three and eight ...

Cognitive decline may begin years before major cardiovascular events in older adults, according to long-term study data.

After adjustments for CAG repeat length and age, pyramidal signs appeared a median of 13.3 years before predicted motor onset. Pyramidal signs appear more than a decade before motor onset in ...

Background Multiple sclerosis (MS) shows marked geographic and ethnic variation, but the contribution of migration status and region of origin to long-term outcomes remains uncertain. We aimed to ...

Federated learning (FL) has the potential to boost deep learning in neuroimaging but is rarely deployed in real-world scenarios, where its true potential lies. We propose FLightcase, a new FL toolbox ...

uniQure has acknowledged that what it called “game changing” data in September showing significant slowing of Huntington’s disease (HD) progression in patients treated with its gene therapy candidate ...

At the Type B end-of-Phase 2 MS meeting with the U.S. Food and Drug Administration, FDA aligned with Clene acknowledging the limitations of the Expanded Disability Status Scale and expressed openness ...

~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external ...

uniQure is targeting a BLA submission in the first quarter of 2026. Topline data were announced from a pivotal phase 1/2 study evaluating AMT-130 in patients with Huntington disease (HD). AMT-130 is a ...